Rochelle Lazarus Purchases Shares in Organon & Co.
Rochelle Lazarus acquired 17,857 shares of Organon & Co. valued at nearly $240,000.
Key Points
- Rochelle Lazarus bought 17,857 shares of Organon & Co. at $13.44 each, totaling $239,998 on June 12, 2026.
- Organon & Co. trades on the NYSE with a market cap of about $3.53 billion and a P/E ratio of 14.45.
- Recent analyst activity includes a hold rating from BNP Paribas with a $14 target price.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Rochelle Lazarus recently made a notable move by purchasing 17,857 shares of Organon & Co. (NYSE:OGN) on June 12, 2026. The transaction was valued at approximately $239,998, with each share purchased at $13.44. This insider transaction was not part of a pre-planned trading program.
Other Institutional Activity in Organon & Co.
Among Organon's institutional investors, BlackRock, Inc. increased its stake by 751,009 shares, bringing its total to 31,717,028 shares valued at about $189.98 million. Vanguard Portfolio Management LLC acquired 21,846,036 shares, now holding shares worth approximately $130.86 million. State Street Corp also added 359,013 shares, totaling 9,956,774 shares valued at around $59.64 million. Conversely, LSV Asset Management trimmed its position by 212,699 shares, leaving it with 7,259,730 shares valued at $43.49 million.
Organon & Co. Stock Down 2.3%
Shares of Organon & Co. are trading at $13.44. The company has a market cap of approximately $3.53 billion and a P/E ratio of 14.45. Its 52-week range is between $5.69 and $13.49. The stock's 50-day moving average is $11.88, and its 200-day moving average is $9.04. Organon has a beta of 1.544, indicating higher volatility compared to the market.
Recent Earnings
In its latest earnings report, Organon & Co. posted revenue of $6.16 billion, reflecting a slight decline of 3.5%. The company achieved a net margin of 3.99% and a return on equity of 34.05%. Earnings per share stood at $0.93. The next earnings announcement is scheduled for August 4, 2026.
Dividend
Organon & Co. offers an annual dividend rate of $0.08 per share, yielding 0.6%. The company's dividend payout ratio is a conservative 8.6%.
Insider Buying and Selling at Organon & Co.
Alongside Rochelle Lazarus, several other insiders made identical purchases on June 12, 2026. Shalini Sharp, Philip Ozuah, Ramona Sequeira, Deborah Leone, and Cynthia Patton each acquired 17,857 shares at the same price of $13.44. These purchases were not part of any pre-arranged trading plans.
Analysts Set New Price Targets
On April 29, 2026, BNP Paribas downgraded Organon & Co. to a hold rating with a target price of $14. Piper Sandler upgraded the stock to hold with a $14 target on April 28, 2026. Barclays maintained a sell rating with an $8 target on February 24, 2026. The consensus among analysts is a hold rating with a mean target price of $11.25.
About Organon & Co.
Organon & Co., headquartered in Jersey City, New Jersey, is a healthcare company specializing in women's health solutions, including contraception and fertility products. The company also offers biosimilars, cholesterol-modifying medicines, and treatments for conditions like asthma and hypertension. Organon serves various markets globally, providing prescription therapies and medical devices.
Bottom Line
Rochelle Lazarus's recent purchase of Organon & Co. shares is a significant insider transaction, reflecting her confidence in the company's prospects. Investors often track such insider activities for potential insights into company performance. However, it's important to remember that insider transactions are just one piece of the puzzle when evaluating a stock.
Get Organon & Co. alerts
New 13F filings, insider trades, and analyst moves on $OGN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.